Steffi Kar Kei Yuen

Chinese University of Hong Kong

Papers

2

Total Citations

6

H-Index

2

About

Steffi Kar Kei Yuen is a rising urologic surgeon-scientist whose work sits at the intersection of surgical innovation and evidence-based oncology. Her primary research focuses on improving perioperative outcomes in prostate cancer surgery and pioneering minimally invasive techniques for benign prostatic hyperplasia. She is best known for leading a prospective, single-center, phase III randomized controlled trial investigating the use of Hemopatch to prevent lymphatic leak after robotic-assisted radical prostatectomy and pelvic lymph node dissection—a common and challenging complication. That study, published in 2022, has already garnered 4 citations and is shaping post-operative protocols. More recently, Yuen has ventured into the frontier of robotic waterjet resection (Aquablation), evaluating its impact on circulating tumor cells in men with localized prostate cancer and lower urinary tract symptoms. Her 2025 paper on this topic, with 2 citations, reflects her commitment to merging functional outcomes with oncologic safety. Through rigorous clinical trial design and a focus on real-world surgical challenges, Yuen is building a reputation as a meticulous investigator whose work directly enhances patient recovery and quality of life after prostate interventions.

Research Focus

Key Achievements

2
H-Index
2
Papers
6
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Hemopatch to Prevent Lymphatic Leak after Robotic Prostatectomy and Pelvic Lymph Node Dissection: A Randomized Controlled Trial
4 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Chinese University of Hong Kong

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago